Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech

Mesoblast

15/04/2026 01:47

** Shares of Mesoblast MSB.AX rise as much as 6% to A$2.13, post their biggest intraday pct gain since March 25

** Drug maker acquires exclusive licence to patented chimeric antigen receptor (CAR) technology platform

** CAR tech for precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell products

** Foundational work on the technology was developed by investigators at U.S.-based Mayo Clinic

** YTD, MSB down 22.4%

 (Reporting by Nichiket Sunil in Bengaluru)

 ((Nichiket.Sunil@thomsonreuters.com))